Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4Unknown 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Uveal Melanoma 2Neoplasms 2Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × Monophenol Monooxygenase × Clear all
NCT00084656 2022-04-14

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Bristol-Myers Squibb

Phase 2 Completed
77 enrolled 13 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00028431 2014-05-22

Novel Adjuvants for Peptide-Based Melanoma Vaccines

University of Southern California

Phase 1 Completed
19 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT00313508 2014-02-21

Dendritic Cell Vaccination During Lymphoid Reconstruction

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00001685 2008-03-04

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
114 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡